Press Releases 2019

Biocon Biologics  /  Press Releases  /  Press Releases 2019

Biocon and Mylan Launch First Insulin Glargine Biosimilar, Semglee®, in Australia

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw Promises to Enable Universal Access to rh-Insulin by Reducing Prices to Less than 10 US cents /Day for LMICs

  • Posted by: Biocon Biologics

Biocon Biologics Expands its R&D Footprint Through Acquisition

  • Posted by: Biocon Biologics

Biocon’s Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity

  • Posted by: Biocon Biologics

Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri™, in Australia

  • Posted by: Biocon Biologics

Biocon Q1FY20 Revenue Rs 1,490 Cr, Up 25%; EBITDA Up 51% at Rs 462 Cr; Net Profit (excluding exceptional item) Up 86% at Rs 223 Cr

  • Posted by: Biocon Biologics

Health Canada Approves Biocon and Mylan’s Ogivri™, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers

  • Posted by: Biocon Biologics

Biocon and Mylan to Present Final Overall Survival Data for OgivriTM(trastuzumab-dkst), a biosimilar to Herceptin®, at the American Society of Clinical Oncology (ASCO) Annual Meeting

  • Posted by: Biocon Biologics

Biocon Q4FY19 Revenue Rs 1,557 Cr, Up 26%; EBITDA Up 43% at Rs 431 Cr; Net Profit Up 64% at Rs 214 Cr FY19 Revenue Up 31% at Rs 5,659 Cr; Net Profit Up 143% at Rs 905 Cr

  • Posted by: Biocon Biologics

Kiran Mazumdar-Shaw Conferred With Honorary Doctorate from Deakin University, Australia

  • Posted by: Biocon Biologics
Share
buy twitter followers